{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-26-001144","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2026-07-07T11:46:22+00:00","discovered_at":"2026-07-07T11:50:00.260089+00:00","generated_at":"2026-07-07T11:50:06.952991+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vivani subsidiary Cortigent to merge into ClearOne in stock deal; Novo Nordisk to evaluate semaglutide implant","bullets":["Cortigent (Vivani subsidiary) to merge into ClearOne (Nasdaq: CLRO) for 12.5M ClearOne shares; Vivani will control combined board.","ClearOne to raise $10M-$15M via unit offering as condition to close; closing expected by Dec 28, 2026.","Vivani enters non-exclusive agreement with Novo Nordisk to evaluate NPM-139 semaglutide implant for chronic weight management.","Phase 1 first-in-human study of NPM-139 expected mid-2026 with Wegovy as active comparator.","Lock-up: 50% of Vivani's ClearOne shares locked 1 year, 50% locked 2 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-26-001144","json":"https://secwatch.observer/filing/0001753926-26-001144.json","markdown":"https://secwatch.observer/filing/0001753926-26-001144.md","text":"https://secwatch.observer/filing/0001753926-26-001144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626001144/0001753926-26-001144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626001144/vani-20260701.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T11:50:06.952991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}